The Defense Logistics Agency Troop Support is seeking sources capable of providing Oseltamivir Phosphate.  DLA Troop Support is contemplating awarding a requirements contract with a one-year base period and a one-year option period for Oseltamivir Phosphate 75MG Capsules in bottles of 10 each.  The estimated annual quantities to be ordered are 625,000 (base period) and 875,000 (option period).  However the quantities may increase or decrease as requirements change.

Must have FDA approval to sell Oseltamivir Phosphate before award of the contract.

If your firm currently manufactures or distributes Oseltamivir Phosphate, please provide information with respect to the following:

a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price
f) Estimated inventory level and storage requirements

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc.  Firms and organizations that currently develop or manufacture Oseltamivir Phosphate or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Oseltamivir Phosphate.  All information submitted shall remain with the U.S. Government and will not be returned.  It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. 

Your response to this RFI may be submitted electronically in pdf format and emailed to [email protected].